Rational engineering of minimally immunogenic nucleases for gene therapy
Abstract Genome editing using CRISPR-Cas systems is a promising avenue for the treatment of genetic diseases.However, cellular Kidney Formulas and humoral immunogenicity of genome editing tools, which originate from bacteria, complicates their clinical use.Here we report reduced immunogenicity (Red)(i)-variants of two clinically relevant nucleases,